Compare ADV & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADV | RLMD |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.2M | 524.9M |
| IPO Year | 2019 | 2012 |
| Metric | ADV | RLMD |
|---|---|---|
| Price | $32.89 | $4.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $45.83 | $12.40 |
| AVG Volume (30 Days) | 108.2K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,542,642,000.00 | $13,070.00 |
| Revenue This Year | $0.63 | N/A |
| Revenue Next Year | $0.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $0.49 | $0.59 |
| 52 Week High | $47.45 | $8.00 |
| Indicator | ADV | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 36.91 |
| Support Level | $0.78 | $4.06 |
| Resistance Level | $44.60 | $5.05 |
| Average True Range (ATR) | 3.60 | 0.31 |
| MACD | -0.42 | -0.01 |
| Stochastic Oscillator | 48.66 | 36.33 |
Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.